Tags

Type your tag names separated by a space and hit enter

Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters.
Cytokine 1997; 9(8):605-12C

Abstract

Ulcerative mucositis is a painful, debilitating and dose-limiting toxicity of cancer chemotherapy. Current treatment is largely palliative and no adequate preventive treatment exists. Recently, we reported that recombinant human(rh) interleukin 11 (IL-11) favourably modified the course of mucositis following a single stomatotoxic regimen of 5-fluorouracil in hamsters. Although potentially beneficial, the clinically relevant issue of mucositis and myelosuppression during multicourse chemotherapy treatment was not addressed. The present study was undertaken to evaluate the effect of rhIL-11 on two consecutive courses of mucositis and myelosuppression in hamsters. Ulcerative mucositis was induced using a standardized protocol consisting of 5-fluorouracil (60 mg/kg) on days 1 and 2 followed by superficial irritation of the buccal mucosa on day 4. Animals treated with 100 microg of rhIL-11 for 12 consecutive days following each regimen of chemotherapy experienced a reduction in the incidence, severity, and duration of mucositis, a reduction in weight loss, and less morbidity and mortality relative to control animals. Bone marrow cellularity and function was not adversely affected by rhIL-11 treatment. The present study is consistent with the potential use of rhIL-11 treating patients at risk of developing ulcerative mucositis while undergoing intensive multicourse chemotherapy treatment.

Authors+Show Affiliations

Division of Oral Medicine Oral and Maxillofacial Surgery, and Dentistry, Brigham & Women's Hospital, Boston, MA 02115, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

9245489

Citation

Sonis, S T., et al. "Mitigating Effects of Interleukin 11 On Consecutive Courses of 5-fluorouracil-induced Ulcerative Mucositis in Hamsters." Cytokine, vol. 9, no. 8, 1997, pp. 605-12.
Sonis ST, Van Vugt AG, McDonald J, et al. Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine. 1997;9(8):605-12.
Sonis, S. T., Van Vugt, A. G., McDonald, J., Dotoli, E., Schwertschlag, U., Szklut, P., & Keith, J. (1997). Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. Cytokine, 9(8), pp. 605-12.
Sonis ST, et al. Mitigating Effects of Interleukin 11 On Consecutive Courses of 5-fluorouracil-induced Ulcerative Mucositis in Hamsters. Cytokine. 1997;9(8):605-12. PubMed PMID: 9245489.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mitigating effects of interleukin 11 on consecutive courses of 5-fluorouracil-induced ulcerative mucositis in hamsters. AU - Sonis,S T, AU - Van Vugt,A G, AU - McDonald,J, AU - Dotoli,E, AU - Schwertschlag,U, AU - Szklut,P, AU - Keith,J, PY - 1997/8/1/pubmed PY - 1997/8/1/medline PY - 1997/8/1/entrez SP - 605 EP - 12 JF - Cytokine JO - Cytokine VL - 9 IS - 8 N2 - Ulcerative mucositis is a painful, debilitating and dose-limiting toxicity of cancer chemotherapy. Current treatment is largely palliative and no adequate preventive treatment exists. Recently, we reported that recombinant human(rh) interleukin 11 (IL-11) favourably modified the course of mucositis following a single stomatotoxic regimen of 5-fluorouracil in hamsters. Although potentially beneficial, the clinically relevant issue of mucositis and myelosuppression during multicourse chemotherapy treatment was not addressed. The present study was undertaken to evaluate the effect of rhIL-11 on two consecutive courses of mucositis and myelosuppression in hamsters. Ulcerative mucositis was induced using a standardized protocol consisting of 5-fluorouracil (60 mg/kg) on days 1 and 2 followed by superficial irritation of the buccal mucosa on day 4. Animals treated with 100 microg of rhIL-11 for 12 consecutive days following each regimen of chemotherapy experienced a reduction in the incidence, severity, and duration of mucositis, a reduction in weight loss, and less morbidity and mortality relative to control animals. Bone marrow cellularity and function was not adversely affected by rhIL-11 treatment. The present study is consistent with the potential use of rhIL-11 treating patients at risk of developing ulcerative mucositis while undergoing intensive multicourse chemotherapy treatment. SN - 1043-4666 UR - https://www.unboundmedicine.com/medline/citation/9245489/Mitigating_effects_of_interleukin_11_on_consecutive_courses_of_5_fluorouracil_induced_ulcerative_mucositis_in_hamsters_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1043-4666(97)90208-8 DB - PRIME DP - Unbound Medicine ER -